Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

(Revival) studie for å undersøke effektiviteten og sikkerheten til alkalisk fosfatase hos pasienter med sepsis-assosiert AKI

26. oktober 2026 oppdatert av: AM-Pharma

En DB, placebokontrollert, to-arms parallell gruppe, fase 3 RCT for å undersøke effektiviteten og sikkerheten til rekombinant human alkalisk fosfatase for behandling av pasienter med SA-AKI

Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis.

The study has three distinct SA-AKI trial populations:

  1. The main trial population: Patients with a pre-AKI reference eGFR ≥45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
  2. A 'moderate' CKD population: Patients with a pre-AKI reference eGFR ≥25 and <45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
  3. A Corona Virus Disease 2019 (COVID-19) population: Patients with proven or suspected SARS-CoV-2 at time of randomization with or without 'moderate' CKD. For patients in this population, COVID-19 should be the main cause of SA-AKI.

In the main study population approximately 1400 patients will be enrolled and in the two cohorts with moderate CKD and COVID-19 each up to 100 patients.

There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.

Studieoversikt

Status

Avsluttet

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Sepsis is the leading cause of acute kidney injury (AKI) and a major cause of death. Patients with SA-AKI have a high mortality and morbidity and are at risk of developing chronic kidney disease. AP is a homodimeric endogenous enzyme present in many cells and organs, e.g., intestines, placenta, liver, bone, kidney, and granulocytes. It exerts detoxifying effects through dephosphorylation of endotoxins; pathogen associated molecular pattern molecules (PAMPS e.g., lipopolysaccharide) and damage-associated molecular pattern molecules (DAMPS e.g., adenosine tri- and di-phosphate). In animal models of sepsis and AKI, administration of AP attenuates the inflammatory response, improves renal function and/or reduces mortality.

AM-Pharma B.V. is developing AP as a novel, recombinant chimeric human AP medicinal product, called recAP, to be used as an intravenous infusion for the treatment of SA-AKI. In the Phase 2 trial STOP-AKI, a survival benefit was observed in the two highest dose groups, 0.8 mg/kg and 1.6 mg/kg groups, compared to the placebo group. There were no safety or tolerability concerns for any of the doses tested (0.4, 0.8 and 1.6 mg/kg). The 1.6 mg/kg recAP dose was selected for this Phase 3 trial based on the significant survival benefit observed. PK/PD simulations also confirmed this dose to have the most pronounced treatment effect.

The primary objective of this Phase 3 trial is to confirm the mortality benefit seen in STOP-AKI by demonstrating a reduction in 28 day all cause mortality in patients with SA-AKI treated with 1.6 mg/kg recAP.

Studietype

Intervensjonell

Registrering (Faktiske)

676

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Bedford Park, Australia, 5042
        • Flinders Medical Centre
      • Bendigo, Australia, 3550
        • Bendigo Hospital
      • Footscray, Australia, 3011
        • Footscray Hospital
      • Melbourne, Australia, 3084
        • Austin Hospital
      • New Lambton Heights, Australia, 2305
        • John Hunter Hospital
      • Saint Albans, Australia, 3021
        • Sunshine Hospital ICU - Western Hospital
      • Southport, Australia, 4215
        • Gold Coast University Hospital (GCUH)
      • Brussels, Belgia, 1020
        • Centre Hospitalier Universitaire Brugmann
      • Charleroi, Belgia, 6042
        • Centre Hospitalier Universitaire (CHU) de Charleroi - Hopital Civil Marie Curie
      • Genk, Belgia, 3600
        • Ziekenhuis Oost-Limburg
      • Ghent, Belgia, 9000
        • Universitair Ziekenhuis Gent
      • Jette, Belgia, 1090
        • Universitair Ziekenhuis Brussel
      • La Louvière, Belgia, 7100
        • Hôpital de JOLIMONT
      • Ottignies, Belgia, 1340
        • Clinique Saint-Pierre- Ottignies
      • Woluwe-Saint-Lambert, Belgia, 1200
        • Cliniques Universitaires Saint-Luc
      • Yvoir, Belgia, 5530
        • CHU UCL Namur - Mont-Godinne
      • Calgary, Canada, T1Y 6J4
        • Peter Lougheed Centre
      • Calgary, Canada, T2N 2T9
        • Foothills Medical Centre
      • Calgary, Canada, T2V 1P9
        • Rockyview General Hospital
      • Calgary, Canada, T3M 1M4
        • Alberta Health Services - South Health Campus Hospital
      • Ottawa, Canada, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Ottawa, Canada, K1Y 4E9
        • The Ottawa Hospital - Civic Campus
      • Québec, Canada, G1J 1Z4
        • Hôpital de l'Enfant-Jésus
      • Vancouver, Canada, V6Z 1Y6
        • St. Paul's Hospital
      • Victoria, Canada, V8R 1J8
        • Royal Jubilee Hospital (RJH)
      • Victoria, Canada, V8R 1J8
        • Victoria General Hospital (VGH)
      • Aalborg, Danmark, 9000
        • Aalborg Universitetshospital
      • Aarhus N, Danmark, 8200
        • Aarhus University Hospital
      • Copenhagen, Danmark, 2100
        • Rigshospitalet
      • Herning, Danmark, 7400
        • Herning Regional Hospital
      • Hillerød, Danmark, 3400
        • Nordsjællands Hospital
      • Køge, Danmark, 4600
        • Sjaellands Universitetshospital, Koge - Kardiologisk Afdeling
      • Odense C, Danmark, 5000
        • Odense Universitetshospital
      • Randers, Danmark, 8930
        • Regionshospitalet Randers
      • Slagelse, Danmark, 4200
        • Slagelse Sygehus
      • Viborg, Danmark, 8800
        • Hospitalsenhed Midt
      • Helsinki, Finland, 290
        • Helsinki University Central Hospital (HUCH)
      • Tampere, Finland, 33521
        • Tampere University Hospital
      • Turku, Finland, 20521
        • Turku University Hospital (TYKS)
    • Arizona
      • Tucson, Arizona, Forente stater, 85724-5057
        • The University of Arizona Cancer Center
    • California
      • Los Angeles, California, Forente stater, 90095-8358
        • Ronald Reagan UCLA Medical Center
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20037-2342
        • The George Washington University Medical Faculty Associates - Anesthesiology
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322-1007
        • Emory Clinical Cardiovascular Research Institute
    • Illinois
      • Glenview, Illinois, Forente stater, 60026-1301
        • Glenbrook Hospital
      • Highland Park, Illinois, Forente stater, 60035
        • NorthShore Medical Group - Bannockburn
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40508-3215
        • University of Kentucky College of Medicine (UKCM)
    • Minnesota
      • Saint Paul, Minnesota, Forente stater, 55101
        • Regions Hospital
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87131
        • University of New Mexico School of Medicine
    • North Carolina
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Wake Forest Baptist Medical Center
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • University of Cincinnati Cancer Institute
      • Columbus, Ohio, Forente stater, 43210
        • The Ohio State University - Dorothy M. Davis Heart and Lung Research Institute
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15213-3108
        • UPMC CancerCenter at Magee - Womens Hospital
      • Pittsburgh, Pennsylvania, Forente stater, 15213-3108
        • UPMC Presbyterian
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908-0817
        • University of Virginia Health System
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226-3522
        • Froedtert & the Medical College of Wisconsin Froedtert Hospital
      • Angers, Frankrike, 49933
        • Centre Hospitalier Universitaire d'Angers
      • Argenteuil, Frankrike, 95107
        • Centre Hospitalier d'Argenteuil
      • Béthune, Frankrike, 62408
        • Centre Hospitalier de Bethune Germon et Gauthier
      • Cergy-Pontoise, Frankrike, 95303
        • Centre Hospitalier René-Dubos
      • Dijon, Frankrike, 21079
        • CHU Dijon - Hôpital François Mitterrand
      • La Roche-sur-Yon, Frankrike, 85000
        • Centre Hospitalier Départemental de Vendée - Les Oudairies
      • Le Kremlin-Bicêtre, Frankrike, 94270
        • Hôpital Bicêtre
      • Le Mans, Frankrike, 72000
        • Centre Hospitalier du Mans
      • Limoges, Frankrike, 87000
        • CHU Limoges - Hôpital Dupuytren
      • Nancy, Frankrike, 54000
        • CHU de Nancy
      • Nantes, Frankrike, 44000
        • CHU de Nantes - Hôtel-Dieu
      • Nîmes, Frankrike, 30029
        • CHU de Nimes - Hopital Universitaire Caremeau
      • Orléans, Frankrike, 45067
        • Hôpital La Source
      • Paris, Frankrike, 75010
        • Hôpital Lariboisière
      • Strasbourg, Frankrike, 67091
        • Hôpitaux Universitaires de Strasbourg - Hôpital Civil
      • Tours, Frankrike, 37044
        • CHRU de Tours - Hôpital Bretonneau
      • Dublin, Irland, D08 NHY1
        • St. James's Hospital
      • Dublin, Irland, D24NR0A
        • Tallaght University Hospital
      • Dublin, Irland, Dublin 4
        • St. Vincent's University Hospital
    • G
      • Galway, G, Irland, H91 YR71
        • National University of Ireland, Galway
      • Hachioji-Shi, Japan, 193-0998
        • Tokyo Medical University Hachioji Medical Center
      • Hiroshima, Japan
        • Hiroshima University Hospital
      • Izuka-shi, Japan, 820-8505
        • Aso Iizuka Hospital
      • Izumisano, Japan, 598-8577
        • Rinku General Medical Center
      • Kashihara-shi, Japan, 634-8522
        • Nara Medical University Hospital
      • Kumamoto, Japan, 860-0008
        • National Hospital Organization Kumamoto Medical Center
      • Osaka, Japan, 534-0021
        • Osaka City General Hospital
      • Osaka, Japan, 543-0035
        • Osaka Police Hospital
      • Toyoake-Shi, Japan, 470-1192
        • Fujita Health University Hospital
      • Yokohama, Japan, 245-8575
        • National Hospital Organization - Yokohama Medical Center
      • Ōmihachiman, Japan, 523-0082
        • Omihachiman Community Medical Center
      • Amsterdam, Nederland, 1081 HV
        • Amsterdam UMC - VUMC
      • Ede, Nederland, 6716 RP
        • Ziekenhuis Gelderse Vallei
      • Enschede, Nederland, KZ 7512
        • Medisch Spectrum Twente
      • Heerlen, Nederland, Heerlen
        • Zuyderland Medisch Centrum, Heerlen
      • Nijmegen, Nederland, 6532 SZ
        • Canisius-Wilhelmina Ziekenhuis
      • Nijmegen, Nederland, 6500 HB
        • Radboud UMC
    • North Brabant
      • 's-Hertogenbosch, North Brabant, Nederland, 5223 GZ
        • Jeroen Bosch Ziekenhuis lokatie GZG
      • Auckland, New Zealand, 1023
        • Auckland City Hospital
      • Auckland, New Zealand, 2025
        • Middlemore Clinical Trials
      • Christchurch, New Zealand, 8140
        • Christchurch Hospital
      • Dunedin, New Zealand, 9016
        • Dunedin Hospital
      • Grafton, New Zealand, 1023
        • Auckland City Hospital
      • Hastings, New Zealand, 4172
        • Hawke's Bay Hospital Soldiers' Memorial
      • Rotorua, New Zealand, 3046
        • Lakes District Health Board - Rotorua Hospital
    • WGN
      • Wellington, WGN, New Zealand, 6021
        • Wellington Hospital
      • Badalona, Spania, 8916
        • Hospital Universitari Germans Trias i Pujol
      • Barcelona, Spania, 8035
        • Hospital Universitario Vall d'Hebron
      • Barcelona, Spania, 8907
        • Hospital Universitari de Bellvitge (IDIBELL)
      • Barcelona, Spania, 8003
        • Hospital del Mar
      • Girona, Spania, 17007
        • Hospital Universitari de Girona Doctor Josep Trueta
      • Madrid, Spania, 28040
        • Hospital Clínico San Carlos
      • Sabadell, Spania, 8208
        • Parc Taulí Sabadell Hospital Universitari
      • Terrassa, Spania, 8221
        • Universitat de Barcelona - Hospital Universitari Mutua Terrassa (HUMT)
      • Cardiff, Storbritannia, CF14 4XW
        • University Hospital of Wales
      • Liverpool, Storbritannia, L7 8XP
        • Royal Liverpool University Hospital
      • London, Storbritannia, SE1 7EH
        • Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital
      • Plymouth, Storbritannia, PL6 8DH
        • Plymouth Hospitals NHS Trust - Derriford Hospital
    • LND
      • London, LND, Storbritannia, NW1 2BU
        • University College London Hospitals NHS Foundation Trust - University College Hospital
      • Aachen, Tyskland, 52074
        • Universitätsklinikum Aachen
      • Hamburg, Tyskland, 20246
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Jena, Tyskland, 7747
        • University Hospital Jena - Klinik fur Neurologie
      • Leipzig, Tyskland, 4103
        • Universitaetsklinikum Leipzig - Klinik und Poliklinik fuer Gastroenterologie und Rheumatologie
      • Münster, Tyskland, 48149
        • University Hospital Münster
      • Graz, Østerrike, 8036
        • Medizinische Universitaet Graz - Klinik fuer Innere Medizin
      • Innsbruck, Østerrike, 6020
        • Medizinische Universität Innsbruck
      • Innsbruck, Østerrike, 6020
        • Medizinische Universitaet Innsbruck - Universitaetsklinik fuer Innere Medizin I

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. 18 years or older.

  2. In the ICU or intermediate care unit for clinical reasons.

  3. Have sepsis requiring vasopressor (norepinephrine, epinephrine, dopamine, phenylephrine, vasopressin, or angiotensin II) therapy, i.e.:

    1. suspected or proven bacterial or viral infection. and
    2. on vasopressor therapy (≥0.1 µg/kg/min norepinephrine or equivalent) for sepsis-induced hypotension for at least one hour despite adequate fluid resuscitation according to clinical judgement. Following the initial one hour on at least 0.1 µg/kg/min norepinephrine or equivalent, any dose of vasopressor counts as vasopressor therapy.

    The combination of a) and b) automatically ensures that patients fulfill the Sepsis 3 criteria as 0.1 µg/kg/min norepinephrine corresponds to a score of +4 on the Cardiovascular sub-score of the SOFA score.

  4. Have AKI according to at least one of the below KDIGO criteria, a to d:

    1. An absolute increase in serum or plasma creatinine (CR) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours.

      or

    2. A relative increase in CR to ≥1.5 times the pre-AKI reference CR value which is known or presumed to have occurred within prior 7 days.

      or

    3. A decrease in urinary output to <0.5 mL/kg/hour for a minimum of 6 hours following adequate fluid resuscitation.

    or d) If the patient does not have a known history of CKD and there is no pre-AKI reference CR value available from the past 12 months available from the past 12 months: a CR value greater or equal to the levels presented in Table 1, with the increase in CR presumed to have occurred within prior 7 days.

  5. Provision of signed and dated ICF in accordance with local regulations.

Exclusion Criteria:

  1. a) At sites where enrolment of 'moderate' CKD patients is allowed, patients with 'severe' CKD defined as a pre-AKI reference eGFR <25 mL/min/1.73 m2 are excluded.

    • For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥25 mL/min/1.73 m2.

    • For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 25-60 mL/min/1.73 m2 can also be used to rule out 'severe' CKD.

      b) At sites where enrolment of 'moderate' CKD patients is NOT allowed, patients with 'moderate' and 'severe' CKD defined as a pre-AKI reference eGFR <45 mL/min/1.73 m2 are excluded.

    • For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥45 mL/min/1.73 m2.

    • For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 45-60 mL/min/1.73 m2 can also be used to rule out 'moderate' and 'severe' CKD.

  2. Advanced chronic liver disease, defined as a Child-Pugh score of 10 to 15 (Class C).

  3. Acute pancreatitis without proven infection.

  4. Urosepsis related to suspected or proven urinary tract obstruction.

  5. Main cause of AKI not sepsis.

  6. Proven or suspected SARS-CoV-2 infection. NOTE: This exclusion criterion does not apply to patients in the COVID-19 population, in which COVID-19 should be the main cause of SA-AKI.

  7. Severe burns requiring ICU treatment.

  8. Severely immunosuppressed, e.g. due to:

    • hematopoietic cell transplantation within past 6 months prior to Screening or acute or chronic graft-versus-host disease
    • solid organ transplantation
    • leukopenia not related to sepsis, i.e., preceding sepsis
    • Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)
    • receiving chemotherapy within 30 days prior to Screening.
  9. At high risk of being LTFU, e.g., due to known current or recent (within the last 6 months) IV drug abuse or known to be homeless.

  10. Limitations to use of mechanical ventilation (MV), RRT or vasopressors and inotropes (NOTE: limitation of cardiopulmonary resuscitation (CPR) only is not an exclusion criterion).

  11. Previous administration of recAP.

  12. Use of a non-marketed drug within the last month or concurrent or planned participation in a clinical trial for a non-marketed drug or device. (NOTE: Co-enrollment or concurrent participation in observational, non-interventional trials using no protocolized treatments or procedures are always allowed. Co-enrollment or concurrent participation in trials using protocolized treatments or procedures, e.g. blood draws, requires pre-approval by the TSC).

  13. Current or planned extracorporeal membrane oxygenation (ECMO).

  14. On RRT >24 hours before start of trial drug.

  15. No longer on vasopressor therapy at time of randomization.

  16. On continuous vasopressor therapy for >72 hours before start of trial drug.

  17. Estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2 based on the most recent available CR sample at time of screening (NOTE: will often be the sample used to diagnose AKI). eGFR should be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. In Japan, the CKD-EPI formula with Japanese coefficient should be used. If local regulations prohibit correcting for race in the calculation of eGFR, it is acceptable to use the formula without correcting for race.

  18. Not feasible to start trial drug within:

    1. 48 hours from AKI diagnosis, when AKI diagnosis precedes start of vasopressor therapy.

      or

    2. 24 hours from AKI diagnosis, when AKI is diagnosed after start of vasopressor therapy.

  19. Pregnant or nursing women.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: placebo

matching placebo

Placebo

Eksperimentell: active

recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions

patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.

Andre navn:
  • ilofotase alfa

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
28-day All-cause Mortality: Main Trial Population
Tidsramme: 28 days

To demonstrate an effect of recAP on 28 day all cause mortality

28 days
28-day All-cause Mortality: Moderate Chronic Kidney Disease Population
Tidsramme: 28 days

To demonstrate an effect of recAP on 28 day all cause mortality

28 days
28-day All-cause Mortality: COVID-19 Population
Tidsramme: 28 days

To demonstrate an effect of recAP on 28 day all cause mortality

28 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Major Adverse Kidney Events 90: Main Trial Population
Tidsramme: 90 Days

Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level.

90 Days
Major Adverse Kidney Events 90: Moderate Chronic Kidney Disease Population
Tidsramme: 90 Days

Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level.

90 Days
Major Adverse Kidney Events 90: COVID-19 Population
Tidsramme: 90 Days

Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level.

90 Days
Major Adverse Kidney Events Through Day 90: Combined Population
Tidsramme: 90 Days

Major Adverse Kidney Events through day 90 (MAKE90A) :

  • death until day 90
  • greater than 25% drop in estimated glomerular filtration rate at Day 90
  • on renal replacement therapy (RRT) at day 90 OR on RRT through Day 28
90 Days
Days Alive and Free of Organ Support Through Day 28: Main Trial Population
Tidsramme: 28 days

Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days)

28 days
Days Alive and Free of Organ Support Through Day 28: Moderate Chronic Kidney Disease Population
Tidsramme: 28 days

Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days)

28 days
Days Alive and Free of Organ Support Through Day 28: COVID-19 Population
Tidsramme: 28 days

Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days)

28 days
Days Alive and Out of the ICU Through Day 28: Main Trial Population
Tidsramme: 28 days

Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).

28 days
Days Alive and Out of the ICU Through Day 28: Moderate Chronic Kidney Disease Population
Tidsramme: 28 days

Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).

28 days
Days Alive and Out of the ICU Through Day 28: COVID-19 Population
Tidsramme: 28 days

Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).

28 days
90-day All Cause Mortality: Main Trial Population
Tidsramme: 90 days

90-Day all-cause mortality

90 days
90-day All Cause Mortality: Moderate Chronic Kidney Disease Population
Tidsramme: 90 days

90-Day all-cause mortality

90 days
90-day All Cause Mortality: COVID-19 Population
Tidsramme: 90 days

90-Day all-cause mortality

90 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: A Legters, AM-Pharma

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. november 2020

Primær fullføring (Faktiske)

18. august 2022

Studiet fullført (Faktiske)

18. august 2022

Datoer for studieregistrering

Først innsendt

28. mai 2020

Først innsendt som oppfylte QC-kriteriene

28. mai 2020

Først lagt ut (Faktiske)

2. juni 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. oktober 2026

Sist bekreftet

1. mai 2024

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • AP-recAP-AKI-03-01

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .